|
US3120564A
(en)
|
1960-01-13 |
1964-02-04 |
American Cyanamid Co |
Alkenoylamino benzophenones
|
|
ZA825719B
(en)
|
1981-09-03 |
1983-06-29 |
Recordati Chem Pharm |
Alkanoylanilides
|
|
JPS58179838A
(ja)
|
1982-04-14 |
1983-10-21 |
Konishiroku Photo Ind Co Ltd |
画像形成方法
|
|
US5256791A
(en)
|
1992-03-02 |
1993-10-26 |
Pfizer Inc. |
Preparation of intermediates in the synthesis of quinoline antibiotics
|
|
DE4341403A1
(de)
|
1993-12-04 |
1995-06-08 |
Basf Ag |
N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
|
|
US5475116A
(en)
|
1994-04-29 |
1995-12-12 |
Pfizer Inc. |
Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones
|
|
JPH0912547A
(ja)
|
1995-06-23 |
1997-01-14 |
Chisso Corp |
ニューキノロン系化合物中間体の製造方法
|
|
AU1671597A
(en)
|
1996-02-13 |
1997-09-02 |
Chugai Seiyaku Kabushiki Kaisha |
Indole derivatives
|
|
JPH1072434A
(ja)
*
|
1996-04-08 |
1998-03-17 |
Nissan Chem Ind Ltd |
２，４−置換アニリン誘導体
|
|
US5968929A
(en)
|
1996-10-30 |
1999-10-19 |
Schering Corporation |
Piperazino derivatives as neurokinin antagonists
|
|
US6184380B1
(en)
|
1999-01-25 |
2001-02-06 |
Pfizer Inc. |
Process for preparing naphthyridones and intermediates
|
|
US7019142B2
(en)
|
1998-01-16 |
2006-03-28 |
Pfizer Inc. |
Process for preparing naphthyridones and intermediates
|
|
US6590118B1
(en)
|
1999-09-29 |
2003-07-08 |
Novo Nordisk A/S |
Aromatic compounds
|
|
HUP0301391A3
(en)
|
2000-02-11 |
2010-03-29 |
Vertex Pharma |
Piperazine and piperidine derivatives pharmaceutical compositions containing them and their use
|
|
ATE324365T1
(de)
*
|
2000-08-31 |
2006-05-15 |
Pfizer |
Phenoxyphenylheterozyklen als serotonin- wiederaufnahmehemmer
|
|
MXPA03003475A
(es)
|
2000-10-19 |
2003-07-14 |
Pfizer Prod Inc |
Derivados puente de piperazina.
|
|
AU2002226634B2
(en)
|
2001-03-30 |
2007-01-25 |
Pfizer Products Inc. |
Pyridazinone aldose reductase inhibitors
|
|
MXPA04001286A
(es)
*
|
2001-08-15 |
2004-05-27 |
Du Pont |
Arilamidas orto-heterociclicas sustituidas para controlar plagas de invertebrados.
|
|
US20040034019A1
(en)
|
2002-08-08 |
2004-02-19 |
Ronald Tomlinson |
Piperazine and piperidine derivatives
|
|
US20040082641A1
(en)
|
2002-10-28 |
2004-04-29 |
Rytved Klaus Asger |
Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
|
|
EP1558245A2
(en)
|
2002-10-28 |
2005-08-03 |
Novo Nordisk A/S |
Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
|
|
WO2004052857A1
(en)
|
2002-12-10 |
2004-06-24 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
|
|
WO2004056811A1
(en)
|
2002-12-23 |
2004-07-08 |
Ranbaxy Laboratories Limited |
Flavaxate derivatives as muscarinic receptor antagonists
|
|
EP1590345A1
(en)
|
2002-12-23 |
2005-11-02 |
Ranbaxy Laboratories, Ltd. |
Xanthine derivatives as muscarinic receptor antagonists
|
|
US7488748B2
(en)
|
2003-01-28 |
2009-02-10 |
Ranbaxy Laboratories Limited |
3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
AU2004281794B2
(en)
|
2003-10-14 |
2010-04-22 |
Pfizer Products Inc. |
Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
|
|
CN1922139B
(zh)
|
2004-02-18 |
2010-12-29 |
杏林制药株式会社 |
双环酰胺衍生物
|
|
CN101005838A
(zh)
|
2004-06-22 |
2007-07-25 |
先灵公司 |
大麻素受体配体
|
|
DE102004039280A1
(de)
*
|
2004-08-13 |
2006-02-23 |
Merck Patent Gmbh |
1,5-Diphenyl-pyrazole
|
|
WO2006024955A1
(en)
|
2004-09-01 |
2006-03-09 |
Pfizer Products Inc. |
Azabicyclic amine histamine-3 receptor antagonists
|
|
US20100016400A1
(en)
|
2004-11-19 |
2010-01-21 |
Naresh Kumar |
Azabicyclic muscarinic receptor antagonists
|
|
CN1944398A
(zh)
|
2005-01-11 |
2007-04-11 |
中国医学科学院药物研究所 |
新的苯甲酰胺类化合物及其制法和药物用途
|
|
JP4193949B2
(ja)
|
2005-04-08 |
2008-12-10 |
ファイザー・プロダクツ・インク |
Ｉ型グリシン輸送阻害剤としての二環式［３．１．０］ヘテロアリールアミド
|
|
US20090124600A1
(en)
|
2005-04-19 |
2009-05-14 |
Layton Mark E |
N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists
|
|
EP1891063B1
(en)
|
2005-05-10 |
2012-07-25 |
Vertex Pharmaceuticals, Inc. |
Bicyclic derivatives as modulators of ion channels
|
|
GB0510204D0
(en)
|
2005-05-19 |
2005-06-22 |
Chroma Therapeutics Ltd |
Enzyme inhibitors
|
|
EP1931633A2
(en)
|
2005-09-05 |
2008-06-18 |
Ranbaxy Laboratories Limited |
Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors
|
|
US20090221664A1
(en)
|
2005-10-19 |
2009-09-03 |
Abhijit Ray |
Pharmaceutical compositions of muscarinic receptor antagonists
|
|
US7560551B2
(en)
|
2006-01-23 |
2009-07-14 |
Amgen Inc. |
Aurora kinase modulators and method of use
|
|
WO2008010061A2
(en)
|
2006-07-17 |
2008-01-24 |
Glenmark Pharmaceuticals S.A. |
3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
|
|
WO2008010238A2
(en)
|
2006-07-21 |
2008-01-24 |
Lupin Limited |
Antidiabetic azabicyclo [3. 1. 0] hexan compounds
|
|
EP2059505A2
(en)
|
2006-09-04 |
2009-05-20 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
|
JP2010513458A
(ja)
|
2006-12-19 |
2010-04-30 |
ファイザー・プロダクツ・インク |
Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
|
|
EP2132196A1
(en)
|
2007-02-26 |
2009-12-16 |
Pfizer Products Inc. |
Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
|
|
WO2008117229A1
(en)
|
2007-03-23 |
2008-10-02 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
|
PA8802501A1
(es)
|
2007-10-31 |
2009-06-23 |
Janssen Pharmaceutica Nv |
Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno, hidrolasa
|
|
WO2009152027A1
(en)
|
2008-06-12 |
2009-12-17 |
Merck & Co., Inc. |
5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition
|
|
NZ592425A
(en)
|
2008-10-29 |
2013-04-26 |
Celgene Corp |
Isoindoline compounds for use in the treatment of cancer
|
|
US9149465B2
(en)
|
2009-05-18 |
2015-10-06 |
Infinity Pharmaceuticals, Inc. |
Isoxazolines as inhibitors of fatty acid amide hydrolase
|
|
AR076687A1
(es)
|
2009-05-18 |
2011-06-29 |
Infinity Pharmaceuticals Inc |
Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen
|
|
CN103140134B
(zh)
|
2010-07-23 |
2015-07-29 |
默沙东公司 |
新吡咯烷衍生的β3肾上腺素能受体激动剂
|
|
WO2013018929A1
(en)
|
2011-08-04 |
2013-02-07 |
Takeda Pharmaceutical Company Limited |
Nitrogen-containing heterocyclic compound
|
|
US9527830B2
(en)
|
2011-09-16 |
2016-12-27 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
|
TWI566701B
(zh)
|
2012-02-01 |
2017-01-21 |
日本農藥股份有限公司 |
芳烷氧基嘧啶衍生物及包含該衍生物作為有效成分的農園藝用殺蟲劑及其使用方法
|
|
EP2925322B1
(en)
|
2012-11-29 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
|
CN105188705A
(zh)
|
2013-03-13 |
2015-12-23 |
密歇根大学董事会 |
包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法
|
|
BR112015022483A2
(pt)
|
2013-03-14 |
2017-07-18 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
|
|
KR101556318B1
(ko)
|
2013-05-15 |
2015-10-01 |
한국과학기술연구원 |
칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체
|
|
WO2014199164A1
(en)
|
2013-06-12 |
2014-12-18 |
Ampla Pharmaceuticals, Inc. |
Diaryl substituted heteroaromatic compounds
|
|
AR105889A1
(es)
|
2015-09-03 |
2017-11-22 |
Actelion Pharmaceuticals Ltd |
Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
|
|
US10696642B2
(en)
|
2015-09-23 |
2020-06-30 |
The General Hospital Corporation |
TEAD transcription factor autopalmitoylation inhibitors
|
|
WO2017096045A1
(en)
|
2015-12-02 |
2017-06-08 |
Kyras Therapeutics, Inc. |
Multivalent ras binding compounds
|
|
KR20180094923A
(ko)
|
2015-12-24 |
2018-08-24 |
교와 핫꼬 기린 가부시키가이샤 |
α, β 불포화 아미드 화합물
|
|
PE20190176A1
(es)
|
2016-05-31 |
2019-02-01 |
Chiesi Farm Spa |
Compuestos de imidazolona como inhibidores de la elastasa de neutrofilos humana
|
|
KR102014320B1
(ko)
|
2016-06-27 |
2019-08-26 |
(주)목우연구소 |
이속사졸린 고리를 포함하는 피리딘계 화합물 및 제초제로서의 이의 용도
|
|
US10793504B2
(en)
|
2016-08-23 |
2020-10-06 |
Recurium Ip Holdings, Llc |
Methods for cross coupling
|
|
AU2017341723B2
(en)
|
2016-10-11 |
2021-12-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
WO2018102751A1
(en)
|
2016-12-02 |
2018-06-07 |
Quentis Therapeutics, Inc. |
Ire1 small molecule inhibitors
|
|
CN111132673A
(zh)
|
2017-05-03 |
2020-05-08 |
维瓦斯治疗公司 |
非稠合三环化合物
|
|
US20200095236A1
(en)
|
2017-05-10 |
2020-03-26 |
Forge Therapeutics, Inc. |
Antibacterial compounds
|
|
JP7221202B2
(ja)
|
2017-06-23 |
2023-02-13 |
協和キリン株式会社 |
α、β不飽和アミド化合物
|
|
US11192865B2
(en)
*
|
2017-08-21 |
2021-12-07 |
Vivace Therapeutics, Inc. |
Benzosulfonyl compounds
|
|
TWI793151B
(zh)
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
|
US10287222B1
(en)
|
2017-10-20 |
2019-05-14 |
Uop Llc |
Process and apparatus for desorbent recovery
|
|
SG11202003827YA
(en)
|
2017-11-01 |
2020-05-28 |
Bristol Myers Squibb Co |
Bridged bicyclic compounds as farnesoid x receptor modulators
|
|
ES2944657T3
(es)
|
2017-11-01 |
2023-06-23 |
Bristol Myers Squibb Co |
Compuestos de alqueno como moduladores del receptor farnesoide X
|
|
US11524943B1
(en)
|
2017-12-06 |
2022-12-13 |
Vivace Therapeutics, Inc. |
Benzocarbonyl compounds
|
|
WO2019152809A1
(en)
|
2018-02-02 |
2019-08-08 |
Vanderbilt University |
Antagonists of the muscarinic acetylcholine receptor m4
|
|
WO2019195959A1
(en)
|
2018-04-08 |
2019-10-17 |
Cothera Biosciences, Inc. |
Combination therapy for cancers with braf mutation
|
|
WO2019204505A2
(en)
|
2018-04-18 |
2019-10-24 |
Theras, Inc. |
K-ras modulators with a vinyl sulfonamide moiety
|
|
WO2019232216A1
(en)
|
2018-05-31 |
2019-12-05 |
Genentech, Inc. |
Therapeutic compounds
|
|
CN112805267B
(zh)
|
2018-09-03 |
2024-03-08 |
豪夫迈·罗氏有限公司 |
用作tead调节剂的甲酰胺和磺酰胺衍生物
|
|
WO2020073031A1
(en)
|
2018-10-05 |
2020-04-09 |
New York University |
Fused bicyclic heterocycles as thereapeutic agents
|
|
US20220402869A1
(en)
|
2018-10-15 |
2022-12-22 |
Dana-Farber Cancer Institute, Inc. |
Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof
|
|
CN113412259A
(zh)
|
2018-10-15 |
2021-09-17 |
紐力克斯治疗公司 |
通过泛素蛋白酶体途径降解btk的双官能化合物
|
|
WO2020087063A1
(en)
|
2018-10-26 |
2020-04-30 |
The Trustees Of Indiana University |
Compounds and methods to attenuate tumor progression and metastasis
|
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN113811300A
(zh)
|
2019-03-15 |
2021-12-17 |
总医院公司 |
Tead转录因子的新型小分子抑制剂
|
|
WO2020206137A1
(en)
|
2019-04-04 |
2020-10-08 |
Dana-Farber Cancer Institute, Inc. |
Cdk2/5 degraders and uses thereof
|
|
CA3132387A1
(en)
|
2019-04-23 |
2020-10-29 |
Dana-Farber Cancer Institute, Inc. |
Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof
|
|
JP2022534426A
(ja)
|
2019-05-31 |
2022-07-29 |
イケナ オンコロジー， インコーポレイテッド |
Ｔｅａｄ阻害剤およびその使用
|
|
CN114502540A
(zh)
|
2019-05-31 |
2022-05-13 |
医肯纳肿瘤学公司 |
Tead抑制剂和其用途
|
|
MX2022005775A
(es)
|
2019-11-13 |
2022-06-09 |
Genentech Inc |
Compuestos terapeuticos y metodos de uso.
|
|
CN115103670A
(zh)
|
2019-12-24 |
2022-09-23 |
达纳-法伯癌症研究所股份有限公司 |
转录增强相关结构域(tead)转录因子抑制剂及其用途
|
|
EP4114830A1
(en)
|
2020-03-04 |
2023-01-11 |
Genentech, Inc. |
Heterobifunctional molecules as tead inhibitors
|
|
EP4164752A1
(en)
|
2020-06-03 |
2023-04-19 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
KR20230131189A
(ko)
|
2020-12-02 |
2023-09-12 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
|
WO2022120355A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead degraders and uses thereof
|
|
CA3205726A1
(en)
|
2021-01-25 |
2022-07-28 |
Alfredo C. Castro |
Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer
|
